approval
saveBLINCYTO (BLINATUMOMAB) — FDA approval
community read0 votes
Sponsor: AMGEN. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 2 completionAbbVie Inc — blinatumomab (Phase I/II Trial Completion)Apr 30, 2026 · 160d ago
- phase 2 completionSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)Apr 25, 2026 · 165d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalOct 21, 2025 · 351d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalApr 29, 2025 · 526d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalDec 17, 2024 · 659d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalFeb 8, 2024 · 972d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1205d ago
- approvalBLINCYTO (BLINATUMOMAB) — FDA approvalJun 20, 2023 · 1205d ago
same company · ±60 days · 6
- approvaleculizumab biosimilar: BKEMV (ECULIZUMAB-AEEB) — FDA approvalMay 28, 2024
- approvaltarlatamab: IMDELLTRA (TARLATAMAB-DLLE) — FDA approvalMay 16, 2024
- approvalENBREL (ETANERCEPT) — FDA approvalJul 22, 2024
- approvalENBREL (ETANERCEPT) — FDA approvalJul 22, 2024
- approvalENBREL (ETANERCEPT) — FDA approvalJul 22, 2024
- approvalapremilast: OTEZLA (APREMILAST) — FDA approvalApr 25, 2024
comments(0)
5-min edit window · permanent after that